VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 701–800 of 1,000
Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer
Yang, J. D., Yan, J., Shao, J., Xu, Q., Meng, F., Chen, F., Ding, N., Du, S., Zhou, S., Cai, J., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s233496 · Cited by 12
“Finally, VEGF induces T cell exhaustion via VEGFR2 in the tumor microenvironment by increasing the expression levels of inhibitory checkpoints, such as PD-1, CTLA-4, Tim-3, and Lag-3.(8) Given the suppressive role of VEGF/VEGFR in T cells, there are some clinical and preclinical studies attempting to restore the funct…”
BackgroundSpagnuolo, A., Palazzolo, G., Sementa, C., & Gridelli, C. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1713092 · Cited by 12
Arvanitakis, K., Papadakos, S. P., Vakadaris, G., Chatzikalil, E., Stergiou, I. Ε., Kalopitas, G., Theocharis, S. E., & Germanidis, G. S. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.36 · Cited by 17
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
Jalil, A., Donate, M., & Mattei, J. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.54 · Cited by 36
Sung, J., & Kim, E. T. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07244-1 · Cited by 15
“[36, 37].”
Grieb, B. C., Goff, L. W., Goyal, L., & Denlinger, C. S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237555 · Cited by 12
New options for combination therapy for advanced non-squamous NSCLC
Rossi, A. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1667233 · Cited by 11
“Bevacizumab in addition to having antiangiogenic activity, has immunomodulatory effects through inhibition of VEGF, including promotion of dendritic cell maturation, normalization of tumor vasculature, which might increase T-cell infiltration, and reprogramming of tumor microenvironment from immune suppressive to immu…”
BackgroundXiao, L., Zhou, J., Liu, H., Zhou, Y., Chen, W., Cui, W., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679262 · Cited by 14
“For example, low dose of cyclophosphamide can inhibit and deplete regulatory T cells and enhance the antitumor activities of CD4 T, CD8 T, natural killer (NK), or dendritic cells (27–29); 5-Fluorouracil and other p53-activating cytotoxic drugs can upregulate the expression and release of tumor-associated immunogen and…”
BackgroundBasics of immunotherapy for epithelial ovarian cancer
Collin-Bund, V., Azaïs, H., Bibi‐Triki, S., Lecointre, L., Bétrian, S., Ángeles, M. A., Eberst, L., Faller, É., Boisramé, T., Bendifallah, S., et al. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2021.102283 · Cited by 13
Saba, N. F., Vijayvargiya, P., Vermorken, J. B., Rodrigo, J. P., Willems, S. M., Zidar, N., de Bree, R., Mäkitie, A. A., Wolf, G. T., Argiris, A. E., et al. (2022) · Cancers · doi:10.3390/cancers14051202 · Cited by 11
“This ultimately leads to the upregulation of regulatory T cells (Tregs) [33].”
BackgroundMougel, A., Méjean, F., Tran, T., Adimi, Y., Galy–Fauroux, I., Kaboré, C., Mercier, E., Urquia, P., Terme, M., Tartour, É., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2110218 · Cited by 12
Self-citationCurrent status and future perspectives of bispecific antibodies in the treatment of lung cancer
Wang, W., Qiu, T., Li, F., & Ren, S. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002460 · Cited by 12
“Targeting VEGF-A enhances inhibition of PD-1 as well as decreases PD-1 expression on intratumoral CD8 T cells.([68]) These observations suggest that anti PD-1 therapy in combination with antiangiogenic therapy in antitumor therapy may be effective.”
BackgroundSchirizzi, A., Leonardis, G. D., Lorusso, V., Donghia, R., Rizzo, A., Vallarelli, S., Ostuni, C., Troiani, L., Lolli, I. R., Giannelli, G., et al. (2023) · Cancers · doi:10.3390/cancers15082376 · Cited by 11
Comunanza, V., Gigliotti, C., Lamba, S., Doronzo, G., Vallariello, E., Martin, V., Isella, C., Médico, E., Bardelli, A., Sangiolo, D., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13450 · Cited by 11
Masetti, M., Al‐Batran, S., Goetze, T. O., Thuss-Patience, P. C., Knorrenschild, J. R., Goekkurt, E., Folprecht, G., Ettrich, T. J., Lindig, U., Luley, K. B., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34894 · Cited by 13
Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma
Frizziero, M., McNamara, M. G., Lamarca, Á., Pihlak, R., Kurup, R., & Hubner, R. A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200422143847 · Cited by 12
Qian, F., & Han, B. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001124 · Cited by 13
“Furthermore, VEGF increases expression of inhibitory receptors, contributing to CTL exhaustion.([41]) Oncogenic signaling through the mitogenactivated protein kinase (MAPK) pathway results in the production of VEGF, IL-1, and IL-8, which inhibits the recruitment and function of T cells.”
BackgroundVadaq, N., de Wijer, L. V., van Eekeren, L. E., Koenen, H. J. P. M., de Mast, Q., Joosten, L. A. B., Netea, M. G., Matzaraki, V., & van der Ven, A. J. A. M. (2022) · iScience · doi:10.1016/j.isci.2022.105089 · Cited by 12
“TGF-b and VEGFA can induce the expression of PD-L1 and its receptors (PD-1), respectively (Du et al., 2021; Song et al., 2014; Voron et al., 2015), promoting immunosuppression duringmalignant transformation.”
BackgroundChen, S., Wei, H., Zhao, W., Jiang, W., Ning, R., Zhou, S., Tan, L., Wang, H., Su, C., He, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059995 · Cited by 13
“Further research indicated that the severe thymic atrophy caused by VEGF-A infusion in a tumor-bearing mouse model was caused by a significant decrease in CD4+/CD8+ thymocytes (45).”
BackgroundHu, J., Chai, X., Wang, D., Shu, S., Magnussen, C. G., Xie, L.-X., & Hu, S. (2019) · Medical Principles and Practice · doi:10.1159/000503166 · Cited by 11
Yoon, H., & Yoo, C. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70208 · Cited by 11
Wang, Z., Zhou, F., Xu, S., Wang, K., & Ding, H. (2023) · Cancer Medicine · doi:10.1002/cam4.6453 · Cited by 9
“55,56 These results may provide a theoretical basis for the use of ICIs and ICIs combined with chemotherapy and anti-angiogenesis in EGFR-mutated NSCLC patients after EGFR-TKI treatment failure.”
BackgroundMeng, L., Li, H., Ji, Y., Yu, P., Wang, Z., Cao, L. K., Shi, B., Shao, Y., Jin, Y., Gao, Y., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03857-5 · Cited by 14
“Research conducted by Voron and colleagues elucidates that targeted therapeutic interventions can mitigate the upregulation of inhibitory receptors, a consequence of VEGF-mediated depletion of CD8 + T cells, denoting a pivotal stride in cancer treatment modalities [32].”
BackgroundVEGF-A in COVID-19: a systematic review and meta-analytical approach to its prognostic value
Bahreiny, S. S., Bastani, M., Keyvani, H., Fard, R. M., Aghaei, M., Mansouri, Z., Karamali, N., Sakhavarz, T., Amraei, M., & Harooni, E. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01583-5 · Cited by 10
“Studies have shown elevated VEGF-A signaling is associated with T-cell exhaustion and dysfunction [64, 65].”
Zhang, X., Ye, X., & Jin, H. (2025) · Antioxidants · doi:10.3390/antiox14060726 · Cited by 19
“VEGF can also induce the increased expression of programmed death-1 (PD-1) on tumor-infiltrating CD8+ T cells through the VEGFR2-PLC γ -calcineurin-NFAT pathway, leading to T cell exhaustion [104].”
Li, Y., Yang, L., & Zd, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104883 · Cited by 14
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma
Zakharia, Y., Zakharia, K., & Rixe, O. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1045411 · Cited by 10
“For instance, VEGF-A produced in the tumor microenvironment enhanced PD-1 expression and enhanced the defect of the immune system to generate an adequate CD8 T-cell response [44].”
BackgroundImmuno-oncology for Hepatocellular Carcinoma
Armstrong, S. A., & He, A. R. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.07.007 · Cited by 10
Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?
Carroll, H. K., Duffy, A. G., & O’Farrelly, C. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1744143 · Cited by 12
A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
Meyo, M. T., Chen, J., Goldwasser, F., Hirsch, L., & Huillard, O. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s263832 · Cited by 13
“VEGF-A reduces proliferation and function and promotes exhaustion of anti-tumor effector T cells.(52,53) Conversely, VEGF-A can favor regulatory T cells tumor infiltration and accumulation.”
BackgroundTran, T., Lavillegrand, J., Lerévérend, C., Esposito, B., Cartier, L., Montabord, M., Tran-Rajau, J., Diedisheim, M., Gruel, N., Ouguerram, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33034-0 · Cited by 16
Self-citationChu, X., Bao, H., Lin, Y.-J., Chen, R., Zhang, Y., Huang, T., He, J., Huangfu, S., Pan, Y., & Ding, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965492 · Cited by 12
“This dependence on VEGF-A production in the TME enhances the expression of inhibitory checkpoints involved in CD8+ Tcell exhaustion, rather than directly on CD8+ T cells (48).”
BackgroundThe strange Microenvironment of Glioblastoma
Brisson, L., Geraldo, L. H., Bikfalvi, A., & Mathivet, T. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.03.007 · Cited by 11
Qin, Z., Huang, Y., Li, Z., Pan, G., Zheng, L., Xiao, X., Wang, F., Chen, J., Chen, X., Lin, X., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0872 · Cited by 13
Butters, O., Young, K., Cunningham, D., Chau, I., & Starling, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00618 · Cited by 12
Zhang, Y., Yuan, Z., Jin, Y., Zhang, W., & Yuan, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122058 · Cited by 10
Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?
Sparchez, Z. A., Radu, P., Bartoş, A., Nenu, I., Crăciun, R., Mocan, T., Horhat, A., Spârchez, M., & Dufour, J. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i12.1896 · Cited by 11
Associating Immunotherapy and Targeted Therapies: Facts and Hopes
Ladoire, S., Rébé, C., & Ghiringhelli, F. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1184 · Cited by 11
Immunotherapy-based combinations: current status and perspectives
Miguel, M. J. D., Mansinho, A., Boni, V., & Calvo, E. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000391 · Cited by 10
Yang, Z., Shi, C., Cheng, D., Wang, Y., Xing, Y. T., Du, F., Wu, F., Jin, Y., Dong, Y., & Li, M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1007960 · Cited by 11
Puttagunta, P., Pamulapati, S. V., Bates, J. E., Gross, J. H., Stokes, W. A., Schmitt, N. C., Steuer, C. E., Teng, Y., & Saba, N. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1310106 · Cited by 10
Wang, R., Tan, G., Lei, D., Li, Y., Gong, J., Tang, Y., Pang, H., Luo, H., & Qin, B. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05677-7 · Cited by 9
“It has also been reported that angiogenesis inhibitors can antagonize the situation in which angiogenesis upregulates the expression of PD-1 on T cells and induces expansion of Tregs and other immune suppressive cells (Voron et al. 2015; Chen and Mellman 2013).”
BackgroundWang, C., Huang, H., Song, Z., Li, Z., Huang, J., Cao, L., Wu, Z., Pan, J., Chen, X., & Shen, X. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf012 · Cited by 14
Zhang, D., Pei, S., Feng, Z., & Xia, G. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06732-8 · Cited by 12
“For example, vascular endothelial growth factor (VEGF-A), a well-known inducer of angiogenesis [55], has been shown to enhance the expression of inhibitory checkpoints such as PD-1, CTLA-4, and Tim3 in CD8 + T cells [56].”
Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma
Wang, Y., Rosell, R., Hirsch, F. R., Lu, S., Govindan, R., Park, K., Peters, S., & Zhang, J. J. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.11.008 · Cited by 15
Unal, B., & Saatcioglu, F. (2025) · Biomarker Research · doi:10.1186/s40364-025-00813-y · Cited by 11
“Hypoxia and a protumorigenic cytokine profile further contribute to immune check-point upregulation [234, 235].”
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
Montemagno, C., Durivault, J., Gastaldi, C., Dufies, M., Vial, V., He, X., Ambrosetti, D., Kamenskaya, A., Négrier, S., Bernhard, J., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13401 · Cited by 9
Bagińska, J., Nau, A. N., Diaz, I. G., Giobbie‐Hurder, A., Weirather, J. L., Vergara, J. A., Abrecht, C., Hallisey, M., Dennis, J., Severgnini, M., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03593-2 · Cited by 11
“High VEGF levels have been associated with CD8 + T-cell exhaustion [3], an increase in regulatory T-cell frequencies (Treg) [4], and outcomes from immune checkpoint inhibition (ICI) [5, 6].”
BackgroundExploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas
Page, C. L., Chung, J. W., Rahimi, K., Köbel, M., Provencher, D. M., & Mes‐Masson, A. (2019) · Current Drug Targets · doi:10.2174/1389450120666191016143836 · Cited by 12
Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
Gopinathan, G., Berlato, C., Lakhani, A., Szabova, L., Pegrum, C., Pedrosa, A., Laforêts, F., Maniati, E., & Balkwill, F. R. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0689 · Cited by 9
Modeling Lung Carcinoids with Zebrafish Tumor Xenograft
Carra, S., Gaudenzi, G., Dicitore, A., Cantone, M. C., Plebani, A., Saronni, D., Zappavigna, S., Caraglia, M., Candeo, A., Bassi, A. L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158126 · Cited by 10
Salani, F., Genovesi, V., Vivaldi, C., Massa, V., Cesario, S., Bernardini, L., Caccese, M., Graziani, J., Berra, D., Fornaro, L., et al. (2022) · Cancers · doi:10.3390/cancers14194896 · Cited by 10
“Similarly, anti-VEGF hampers T-reg activity by blocking their VEGFR2 [41] and by reversing MDSCs-dependent T-reg de novo development [42].”
BackgroundWhat Is the Role of Body Composition Assessment in HCC Management?
Radu, P., Ebadi, M., Montaño‐Loza, A. J., & Dufour, J. (2022) · Cancers · doi:10.3390/cancers14215290 · Cited by 10
“Later, other authors confirmed that sarcopenia was a strong and independent prognostic factor for mortality after curative HCC resection [39,40].”
BackgroundBinding of the placental growth factor to VEGF receptor type 1 modulates human T cell functions
Leplina, O. Y., Smetanenko, E. A., Tikhonova, M. A., Васильевич, Б. Е., Викторовна, Т. Т., Михайловна, П. Н., Ostanin, A. A., & Chernykh, E. R. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2a0420-723rr · Cited by 9
Sung, P. S., Cho, S. W., Lee, J., Yang, H., Jang, J. W., Bae, S. H., Choi, J. Y., & Yoon, S. K. (2020) · Journal of Liver Cancer · doi:10.17998/jlc.20.2.128 · Cited by 9
“Moreover, recent reports have demonstrated that the expression of PD-1 and other inhibitory checkpoints is upregulated by VEGF-A secreted by cancer and stromal cells and that immune regulatory function is disrupted when VEGF receptor signaling is targeted with VEGF receptor inhibitors.(23,24) These studies suggest tha…”
BackgroundAngiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease
Holtan, S. G., & Arora, M. (2015) · Translational research · doi:10.1016/j.trsl.2015.06.001 · Cited by 9
“identified enhanced inhibitory checkpoint receptors on cytotoxic CD8+ T-lymphocytes – a mechanism by which VEGF-A exerts its immune modulatory effects on T cells [46].”
BackgroundZhuo, X., Huang, C., Su, L., Liang, F., Xie, W., Xu, Q., Han, P., Huang, X., & Wong, P. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04848-2 · Cited by 8
“In addition, TECs are shown to secrete IFN-γ and VEGF-A to modulate T cell responses (Bourhis et al. 2021; Voron et al. 2015), while Sakano et al.”
BackgroundHuffman, B. M., Rahma, O. E., Tyan, K., Li, Y. Y., Giobbie‐Hurder, A., Schlechter, B. L., Bockorny, B., Manos, M. P., Cherniack, A. D., Bagińska, J., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1027 · Cited by 9
Focus on mechano-immunology: new direction in cancer treatment
Zhao, L., Gui, Y., & Deng, X. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002224 · Cited by 12
“VEGF-A increased the expression of PD-1 in VEGFR + and CD8 + T cells, thereby demonstrating its capability to suppress anti-tumor immune responses [ 81 , 82 ] .”
Lin, S., Hong, M., Zhang, J., Zhao, W., Li, K., Wu, C. F., Yang, Q., Yi, X., Huang, L., Wang, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1612547 · Cited by 11
Khalil, M., & Tsao, M. (2025) · Cancers · doi:10.3390/cancers17132199 · Cited by 9
“In murine tumour models, elevated VEGF-A levels increased PD-1 on CD8 + T cells via VEGFR2 and downstream NFAT-dependent pathways, and blockade of VEGF-A/VEGFR reversed this upregulation and alleviated T cell exhaustion [171].”
Herr, F. L., Antons, M. J., Blume, L. V., Hirner-Eppeneder, H., Kloiber-Langhorst, S., Cimic, A., Stueckl, J., Tardy, I., Burkard, T., Ricke, J., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326675 · Cited by 10
Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
Silva-Romeiro, S., Flores-Campos, R., Sánchez-León, M. L., Sánchez‐Margalet, V., & de la Cruz‐Merino, L. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485642 · Cited by 12
“116,119,120 These findings support the integration of antiangiogenic agents and TKIs as part of combination strategies aimed at depleting MDSCs and overcoming immunosuppression in VEGF-driven tumors.”
Lei, L., Long, J., Chen, C., Zheng, B., Lin, X., Fang, P., Chen, M., Jiang, X., Wang, Y., & Wang, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117574 · Cited by 8
Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma
Khaleel, S. S., Jiang, S., Kotecha, R. R., & Hakimi, A. A. (2022) · Frontiers in Urology · doi:10.3389/fruro.2022.864778 · Cited by 10
Li, J., Zhang, D., Liu, Z., Wang, Y., Li, X., Wang, Z., Liang, G., Yuan, X., Li, Y., Komorowski, A. L., et al. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6446 · Cited by 8
“…angiogenesis, the increased expression of VEGF directly inhibits the trafficking and proliferation of T lymphocytes, inhibits the differentiation and maturation of dendritic cells and antigen presentation, inhibit the activation of T cells and reduce the immune response to tumor cells (42,43).”
Immunologically relevant effects of radiation therapy on the tumor microenvironment
Galassi, C., Klapp, V., Formenti, S. C., Demaria, S., & Galluzzi, L. (2023) · Essays in Biochemistry · doi:10.1042/ebc20220248 · Cited by 8
Wang, G., Ji, X., Wang, H., Tang, X., Xing, X., & Ji, J. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.03.09 · Cited by 9
Johnson, R. L., Ganesan, S., Thangavelu, A., Theophilou, G., Jong, D. D., Hutson, R., Nugent, D., Broadhead, T., Laios, A., Cummings, M., et al. (2023) · Cancers · doi:10.3390/cancers15184632 · Cited by 12
“A phase II randomised trial is currently recruiting MMRd recurrent EC patients to receive nivolumab with or without ipilimumab (NCT05112601) [103].”
Wang, L., Du, C., Jiang, B., Chen, L., & Wang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1256740 · Cited by 10
Hwang, S. Y., Woo, H. Y., Heo, J., Kim, H. J., Park, Y. J., Yi, K. Y., Lee, Y. R., Park, S. Y., Chung, W. J., Jang, B. K., et al. (2024) · Cancers · doi:10.3390/cancers16040838 · Cited by 8
Zhao, Y., Bai, J. Y., Wang, X., Zhang, Y., Yan, X., Qi, J., Xia, X., Feng, Y., & Duan, B. (2024) · Journal of Cancer · doi:10.7150/jca.93885 · Cited by 9
Immunotherapy in Non-Small-Cell Lung Cancer: A Bridge Between Research and Clinical Practice
Passiglia, F., Commendatore, O., Vitali, M., & Conca, R. (2018) · Future Oncology · doi:10.2217/fon-2018-0098 · Cited by 10
Zhou, S., & Zhang, H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200207091653 · Cited by 7
Zhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 9
“The existing evidence suggests that VEGF/VEGFR signaling decreases the proliferation of T cells and increases the expression of PD-1 on CD8+ T cells [26].”
BackgroundCurrent and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
Gonzalez, N. S., Castet, F., Élez, E., Macarulla, T. M., & Tabernero, J. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021772 · Cited by 10
“Local ablation or TACE increases the release of antigens, proinflammatory cytokines and proangiogenic factors (such as VEGF-A and HIF1) which promote an immune response that can be further sustained by increasing the activation of cytotoxic cells through immune checkpoint inhibition and decreasing the infiltration of…”
BackgroundInfluentialTanizaki, S., Matsumoto, K., Tamiya, A., Taniguchi, Y., Matsuda, Y., Uchida, J., Ueno, K., Kawachi, H., Tamiya, M., Yanase, T., et al. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03452-0 · Cited by 9
“VEGF also suppresses T cell in�ltration into tumors by decreasing the expression of adhesion molecules, such as integrin ligand, which is termed tumor endothelial cell allergy [28–29].”
BackgroundMcNamara, B. C., Chang, Y., Mutlu, L., Harold, J. A., & Santin, A. D. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2182679 · Cited by 8
“AntiVEGF therapy has been linked to an increased PD-L1 expression in tumor models [55,56].”
BackgroundShining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors
Qiao, M., Jiang, T., & Zhou, C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.99 · Cited by 8
“VEGF, a proangiogenic molecule plays a key role in the process of angiogenesis, however, it also acts as a key mediator in a development of immunosuppressive microenvironment (29,30).”
BackgroundKonjević, G. M., Vuletić, A. M., Martinović, K. M., Krivokuća, A., Jankovic, R. N., & Babović, N. L. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-9977-7 · Cited by 9
“Moreover, our novel finding showing VEGFRc1 gene expression in lymphocytes of MM patients (unpublished data) supports the recently shown direct suppressive effect of VEGFA on immune cells (Voron et al. 2015).”
ResultXiao, Y., Deng, W., Luo, L., Zhu, G., Xie, J., Liu, Y., Wan, R., Wen, W., Hu, Z., & Shan, R. (2024) · BMC Cancer · doi:10.1186/s12885-024-12355-x · Cited by 8
Sweis, R. F., Chatta, G. S., Jain, R., Moon, H., Delacroix, S. E., Fang, A., D’Amico, L., Kask, A. S., Cheever, M. A., Fling, S. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1728 · Cited by 7
Kokkotou, E., Grapsa, D., Papadopoulou, A., Gaitanakis, S., Bakakos, P., Poulakou, G., Moutsatsou, P., & Syrigos, K. (2025) · Cancers · doi:10.3390/cancers17030421 · Cited by 10
“…activity, may enhance immune system suppression in the tumor microenvironment (TME), as previously reported; more specifically, VEGF-A produced by tumor cells may enhance the expression of PD-1 and other inhibitory checkpoint molecules involved in the inactivation of CD8+ T cells [21].”
Pang, L., Zhuang, W., Chen, Z., Liao, J., Li, M.-D., Zhang, L., Fang, W., & Zhang, Y. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7092 · Cited by 10
Wu, S., Wei, Y., Qiu, Y., Ai, K., Chen, M., Wang, H., Zhang, H., Cen, Q., Liao, P., Ding, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-05907-z · Cited by 15
Bispecific antibody for lung cancer: mechanisms and clinical insights
Chen, W., Zhou, A., & Zhou, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1572802 · Cited by 13
Varlotto, J. M., Wang, Y., Sun, Z., Wakelee, H. A., Ramalingam, S. S., & Schiller, J. H. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100274 · Cited by 7
Mahanti, K., & Bhattacharyya, S. (2023) · Translational research · doi:10.1016/j.trsl.2023.10.003 · Cited by 7
Bai, Z., Yu, X., Tang, Q., Zhang, R., Shi, X.-D., & Liu, C. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0159 · Cited by 8
Wu, F.-D., Zhou, H.-F., Yang, W., Zhu, D., Wu, B., Shi, H., Liu, S., & Zhou, W.-Z. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i1.96267 · Cited by 11
Zhang, C., Wang, H., Li, X., Jiang, Y., Sun, G., & Yu, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1526407 · Cited by 15
“Tumor-derived VEGF, when combined with tumor-associated macrophages, can induce high expression of PD-1 and CTLA-4 on the surface of CD8+ T cells, leading to resistance to PD-1 and PD-L1 therapy (57).”
Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma
Yu, S. J., & Greten, T. F. (2020) · Journal of Liver Cancer · doi:10.17998/jlc.20.1.1 · Cited by 8
Yoshida, H., Kim, Y. H., Sakamori, Y., Nagai, H., Ozasa, H., Kaneda, T., Yoshioka, H., Nakagawa, H., Tomii, K., Okada, A., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14278 · Cited by 7
He, Q., Li, J., Zhang, C., Tang, S., & Qinglan, R. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1975 · Cited by 6
“VEGF can also reduce the expression of PD-1 on killer T cells (10) and inhibit the maturation of dendritic cells (11).”
BackgroundMa, Z., Li, H., & Liu, L. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815999201231215311 · Cited by 7
Cutting the umbilical cord: Cancer stem cell-targeted therapeutics
Banik, A., Sharma, R., Chauhan, A., & Singh, S. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120502 · Cited by 8
Xu, L., Li, W., Yang, T., Hu, S., Zou, Q., Jiao, J., Jiang, N., & Zhang, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.807622 · Cited by 8
“VEGF was the most important angiogenesis factor, which inhibited antigen presentation, promoted regulatory T cell infiltration, and induced PD-L1 expression on tumor-infiltrating T cells (Voron et al., 2015).”
BackgroundRobillard, L., Liao, M., Nguyen, M., Harding, T. C., Simmons, A. D., & Dusek, R. L. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000427 · Cited by 9
Iso, H., Miyanaga, A., Kadoma, N., Shinbu, K., Tozuka, T., Murata, A., Nishima, S., Sato, Y., Nakamichi, S., Matsumoto, M., et al. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s404035 · Cited by 9
Moshe, D. L., Baghaie, L., Leroy, F., Skapinker, E., & Szewczuk, M. R. (2023) · Biomedicines · doi:10.3390/biomedicines11082142 · Cited by 8
“CD8+ T-cell exhaustion can occur due to the expression of negative immune checkpoints such as PD-1, CTLA-4, T-cell immunoglobulin mucin receptor 3, and lymphocyte activation gene 3 protein [41,46].”
Background
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.